Dissecting genetic predisposition to inflammatory bowel disease: Current progress and prospective application

Research output: Contribution to journalArticle

Abstract

Over the last 10 years, sensitive advancement has been made in the study of genetic susceptibility to inflammatory bowel disease (IBD). Complementary methodologies of linkage, fine-mapping and candidate-gene studies have led to the identification of a number of susceptibility genes and loci, including caspase activation and recruitment domain 15 (CARD 15), major histocompatibility complex (MHC) and IBD5, whereas many other genes (nucleotide oligomerization domain 1 (NOD1), tumor-upregulated CARD-containing antagonist of caspase-9 (TUCAN), Toll-like receptors (TLR), interleukin 23 receptor (IL23R), multidrug resistance 1 (MDR1), myosin IXb (MYO9B), chemokine (C-Cmotif) ligand 20 (CCL20), human β-defensin 2 (HBD-2), autophagy-related 16-like 1 (ATG16L1)) are still awaiting confirmation. The CARD15 gene is currently the most widely replicated and investigated gene. The exact sequence of events that link CARD15 variants to early pathogenetic changes is unknown. However, the role of the encoded protein confirms the relevance of appropriate responses by the innate immune system to intestinal bacteria, including the production of antimicrobial peptides (defensins). With the implementation of new genomics and proteomics methodologies, genetic research will advance our further understanding of the clinical heterogeneity of IBD and tackle the complex interactions between genetic and environmental risk factors.

Original languageEnglish
Pages (from-to)287-298
Number of pages12
JournalExpert Review of Clinical Immunology
Volume3
Issue number3
DOIs
Publication statusPublished - May 2007

Fingerprint

Genetic Predisposition to Disease
Inflammatory Bowel Diseases
Defensins
Genes
C Chemokines
Interleukin Receptors
Interleukin-23
Genetic Research
Caspase 9
Chromosome Mapping
Toll-Like Receptors
Autophagy
Multiple Drug Resistance
Myosins
Genomics
Major Histocompatibility Complex
Proteomics
Immune System
Nucleotides
Ligands

Keywords

  • Association study
  • Crohn's disease
  • Inflammatory bowel disease
  • Linkage study
  • NOD1/CARD4 gene
  • NOD2/CARD15 gene
  • Ulcerative colitis
  • Whole genome association study

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

@article{ae40ea7664b945eaabf95e0982baf597,
title = "Dissecting genetic predisposition to inflammatory bowel disease: Current progress and prospective application",
abstract = "Over the last 10 years, sensitive advancement has been made in the study of genetic susceptibility to inflammatory bowel disease (IBD). Complementary methodologies of linkage, fine-mapping and candidate-gene studies have led to the identification of a number of susceptibility genes and loci, including caspase activation and recruitment domain 15 (CARD 15), major histocompatibility complex (MHC) and IBD5, whereas many other genes (nucleotide oligomerization domain 1 (NOD1), tumor-upregulated CARD-containing antagonist of caspase-9 (TUCAN), Toll-like receptors (TLR), interleukin 23 receptor (IL23R), multidrug resistance 1 (MDR1), myosin IXb (MYO9B), chemokine (C-Cmotif) ligand 20 (CCL20), human β-defensin 2 (HBD-2), autophagy-related 16-like 1 (ATG16L1)) are still awaiting confirmation. The CARD15 gene is currently the most widely replicated and investigated gene. The exact sequence of events that link CARD15 variants to early pathogenetic changes is unknown. However, the role of the encoded protein confirms the relevance of appropriate responses by the innate immune system to intestinal bacteria, including the production of antimicrobial peptides (defensins). With the implementation of new genomics and proteomics methodologies, genetic research will advance our further understanding of the clinical heterogeneity of IBD and tackle the complex interactions between genetic and environmental risk factors.",
keywords = "Association study, Crohn's disease, Inflammatory bowel disease, Linkage study, NOD1/CARD4 gene, NOD2/CARD15 gene, Ulcerative colitis, Whole genome association study",
author = "Vito Annese and Anna Latiano and Orazio Palmieri and Angelo Andriulli",
year = "2007",
month = "5",
doi = "10.1586/1744666X.3.3.287",
language = "English",
volume = "3",
pages = "287--298",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Dissecting genetic predisposition to inflammatory bowel disease

T2 - Current progress and prospective application

AU - Annese, Vito

AU - Latiano, Anna

AU - Palmieri, Orazio

AU - Andriulli, Angelo

PY - 2007/5

Y1 - 2007/5

N2 - Over the last 10 years, sensitive advancement has been made in the study of genetic susceptibility to inflammatory bowel disease (IBD). Complementary methodologies of linkage, fine-mapping and candidate-gene studies have led to the identification of a number of susceptibility genes and loci, including caspase activation and recruitment domain 15 (CARD 15), major histocompatibility complex (MHC) and IBD5, whereas many other genes (nucleotide oligomerization domain 1 (NOD1), tumor-upregulated CARD-containing antagonist of caspase-9 (TUCAN), Toll-like receptors (TLR), interleukin 23 receptor (IL23R), multidrug resistance 1 (MDR1), myosin IXb (MYO9B), chemokine (C-Cmotif) ligand 20 (CCL20), human β-defensin 2 (HBD-2), autophagy-related 16-like 1 (ATG16L1)) are still awaiting confirmation. The CARD15 gene is currently the most widely replicated and investigated gene. The exact sequence of events that link CARD15 variants to early pathogenetic changes is unknown. However, the role of the encoded protein confirms the relevance of appropriate responses by the innate immune system to intestinal bacteria, including the production of antimicrobial peptides (defensins). With the implementation of new genomics and proteomics methodologies, genetic research will advance our further understanding of the clinical heterogeneity of IBD and tackle the complex interactions between genetic and environmental risk factors.

AB - Over the last 10 years, sensitive advancement has been made in the study of genetic susceptibility to inflammatory bowel disease (IBD). Complementary methodologies of linkage, fine-mapping and candidate-gene studies have led to the identification of a number of susceptibility genes and loci, including caspase activation and recruitment domain 15 (CARD 15), major histocompatibility complex (MHC) and IBD5, whereas many other genes (nucleotide oligomerization domain 1 (NOD1), tumor-upregulated CARD-containing antagonist of caspase-9 (TUCAN), Toll-like receptors (TLR), interleukin 23 receptor (IL23R), multidrug resistance 1 (MDR1), myosin IXb (MYO9B), chemokine (C-Cmotif) ligand 20 (CCL20), human β-defensin 2 (HBD-2), autophagy-related 16-like 1 (ATG16L1)) are still awaiting confirmation. The CARD15 gene is currently the most widely replicated and investigated gene. The exact sequence of events that link CARD15 variants to early pathogenetic changes is unknown. However, the role of the encoded protein confirms the relevance of appropriate responses by the innate immune system to intestinal bacteria, including the production of antimicrobial peptides (defensins). With the implementation of new genomics and proteomics methodologies, genetic research will advance our further understanding of the clinical heterogeneity of IBD and tackle the complex interactions between genetic and environmental risk factors.

KW - Association study

KW - Crohn's disease

KW - Inflammatory bowel disease

KW - Linkage study

KW - NOD1/CARD4 gene

KW - NOD2/CARD15 gene

KW - Ulcerative colitis

KW - Whole genome association study

UR - http://www.scopus.com/inward/record.url?scp=34249741532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249741532&partnerID=8YFLogxK

U2 - 10.1586/1744666X.3.3.287

DO - 10.1586/1744666X.3.3.287

M3 - Article

C2 - 20477673

AN - SCOPUS:34249741532

VL - 3

SP - 287

EP - 298

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 3

ER -